Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.39 |
| ▸ | DRD3 | P35462 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2780197 | 0.87 | KDR (0.45) | PARP1PLA2G2A | |
| SCHEMBL2779985 | 0.81 | KDR (0.46) | PARP1 | |
| SCHEMBL7906406 | 0.79 | DRD2 (0.45) | PARP1DRD3DRD2KDM4E | |
| SCHEMBL2782521 | 0.74 | KDR (0.44) | PARP1 | |
| SCHEMBL3064920 | 0.73 | PARP1 (0.48) | PARP1KDM4E | |
| SCHEMBL3050598 | 0.72 | DRD2 (0.43) | DRD3DRD2HTR6 | |
| SCHEMBL3049590 | 0.70 | PARP1 (0.49) | PARP1 | |
| SCHEMBL3059195 | 0.70 | PARP1 (0.45) | PARP1GAA | |
| SCHEMBL2780321 | 0.70 | PARP1 (0.45) | PARP1 | |
| SCHEMBL3059082 | 0.70 | PARP1 (0.42) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261706-A1 | SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-10-14 | — | — | US | claimed |
| US-20100261706-A1 | SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261706-A1 | SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF | TNNI3, TNNT2, ALDH1A2 | PARP1 245/4885PLA2G2A 3559/4885DRD3 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.